930. COVID-19 symptom and viral load rebound among individuals reporting nirmatrelvir/ritonavir use compared to propensity score matched individuals not taking COVID-19 treatment

BACKGROUND: Nirmatrelvir/ritonavir (N/R) protects against severe outcomes after SARS-CoV-2 (SCV2) infection, but patients and studies have described symptom and viral rebound after treatment. Our aim was to compare symptom and viral trajectories during acute illness among individuals with COVID-19 t...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith-Jeffcoat, Sarah E, Biddle, Jessica E, Talbot, H Keipp, Olivo, Vanessa, Sano, Ellen, Goodman, Sara H, Petrie, Joshua, Ledezma, Karla I, Bullock, Ayla, Rao, Suchitra, Mellis, Alexandra, Johnson, Sheroi, Kirking, Hannah L, Rolfes, Melissa A, Zhu, Yuwei, Schmitz, Jonathan, Hart, Kimberly W, Battan-Wraith, Steph, Merrill, Lori S, McLaren, Son H, Vargas, Celibell, Sarnquist, Clea, Govindaranjan, Prasanthi, Belongia, Edward, Pryor, Kathleen, Lutrick, Karen, Yang, Amy, Haehnel, Quenla, Asturias, Edwin J, Bowman, Natalie M, Ellingson, Katherine, McLean, Huong, Maldonado, Yvonne A, Stockwell, Melissa, Morrissey, Kerry Grace, Grijalva, Carlos G, Salvatore, Phillip P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678007/
http://dx.doi.org/10.1093/ofid/ofad500.975

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678007/
http://dx.doi.org/10.1093/ofid/ofad500.975

Ejemplares similares